Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 213.95
(-1.86%)
INR 213.95
(-1.86%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.08 Billion | -691.2 Million | -2.08 Billion | -1.51 Billion | -2.1 Billion | -1.71 Billion |
| Net Income | -3.87 Billion | -2.22 Billion | -2.03 Billion | -1.51 Billion | -3.12 Billion | -1.45 Billion |
| Depreciation & Amortization | 125.1 Million | 117.7 Million | 101.61 Million | 109.23 Million | 94.8 Million | 75.52 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -273.4 Million | 1.41 Billion | -260.52 Million | -478.76 Million | 1.02 Billion | -1.7 Million |
| Other non-cash items | 93.1 Million | 5.8 Million | 110.53 Million | 361.96 Million | -98.99 Million | -338.65 Million |
| Investing Cash Flow | 3.69 Billion | -5.48 Billion | -291.67 Million | 15.61 Million | 1.55 Billion | -1.02 Billion |
| Investments in PPE | -265.1 Million | -153.9 Million | -326.77 Million | -59.95 Million | -540.42 Million | -129.51 Million |
| Acquisitions | 4.9 Million | 23.4 Million | 17 Thousand | -55 Thousand | 540.42 Million | 35.2 Million |
| Investment purchases | -250 Million | -10.55 Billion | -47.75 Million | -50 Thousand | -1.04 Million | -1.18 Billion |
| Sales/Maturities of investments | 4.2 Billion | 5.2 Billion | 50 Thousand | 27.37 Million | 2.09 Billion | 261.3 Million |
| Other Investing Activities | 1000.00 | -1000.00 | 82.8 Million | 48.3 Million | -536.19 Million | -7000.00 |
| Financing Cash Flow | 440.2 Million | 6.16 Billion | 2.29 Billion | 1.59 Billion | 554.61 Million | 2.74 Billion |
| Debt repayment | -469.6 Million | -2.99 Billion | -2.62 Billion | -2.37 Billion | -25.74 Million | -6.49 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -119 Thousand | -916.66 Million |
| Common Stock Issuance | - | 7.02 Billion | 4.09 Billion | - | - | 2.74 Billion |
| Other Financing Activities | -16.03 Million | 2.13 Billion | 826.06 Million | 3.96 Billion | 580.48 Million | 1.83 Billion |
| Accounts receivables | 152.1 Million | -50.06 Million | -101.45 Million | -15.43 Million | -58.31 Million | 74.04 Million |
| Accounts payables | -58.9 Million | 766.67 Million | -193.57 Million | -601.75 Million | 717.75 Million | -194.01 Million |
| Inventory | - | 19 Thousand | - | - | - | - |
| Other working capital | -366.6 Million | 694.46 Million | 34.5 Million | 138.43 Million | 360.72 Million | 118.26 Million |
| Cash at beginning of period | 5.85 Million | 12.2 Million | 93.04 Million | 3.52 Million | 3.49 Million | 2.03 Million |
| Cash at end of period | 1.55 Billion | 5.8 Million | 12.24 Million | 93.04 Million | 3.52 Million | 3.49 Million |
| Capital Expenditure | -265.1 Million | -153.9 Million | -326.77 Million | -59.95 Million | -540.42 Million | -129.51 Million |
| Effect of forex changes on cash | 20 Thousand | - | -17 Thousand | 17 Thousand | - | - |
| Net cash flow / Change in cash | 1.54 Billion | -6.4 Million | -80.8 Million | 89.52 Million | 27 Thousand | 1.46 Million |
| Free Cash Flow | -4.34 Billion | -845.1 Million | -2.4 Billion | -1.57 Billion | -2.64 Billion | -1.84 Billion |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -959 Million | -3.87 Billion | -1.05 Billion | -996.5 Million | -864.2 Million | -953.5 Million |
| Depreciation & Amortization | - | 125.1 Million | - | 31.6 Million | 31.8 Million | 31 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -273.4 Million | - | - | - | - |
| Other non-cash items | 959 Million | 93.1 Million | 1.05 Billion | 996.5 Million | 864.2 Million | 953.5 Million |
| Investing Cash Flow | - | 3.69 Billion | - | - | - | - |
| Investments in PPE | - | -265.1 Million | - | - | - | - |
| Acquisitions | - | 4.9 Million | - | - | - | - |
| Investment purchases | - | -250 Million | - | - | - | - |
| Sales/Maturities of investments | - | 4.2 Billion | - | - | - | - |
| Other Investing Activities | - | 1000.00 | - | - | - | - |
| Financing Cash Flow | - | 440.2 Million | - | - | - | - |
| Debt repayment | - | -469.6 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -16.03 Million | - | - | - | - |
| Accounts receivables | - | 152.1 Million | - | - | - | - |
| Accounts payables | - | -58.9 Million | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | -366.6 Million | - | - | - | - |
| Cash at beginning of period | - | 5.85 Million | - | 2.14 Billion | 2.08 Billion | 5.85 Million |
| Cash at end of period | - | 1.55 Billion | - | 2.21 Billion | 2.14 Billion | 67.85 Million |
| Capital Expenditure | - | -265.1 Million | - | - | - | - |
| Effect of forex changes on cash | - | 20 Thousand | - | - | - | - |
| Net cash flow / Change in cash | - | 1.54 Billion | - | 63.2 Million | 63.6 Million | 62 Million |
| Free Cash Flow | - | -4.34 Billion | - | 63.2 Million | 63.6 Million | 62 Million |
CLGOF
OTM
AVIV
600448
VIVR3
CRAB